The Philadelphia jury deliberating in the first punitive damages trial over Johnson & Johnson’s conduct in marketing the antispychotic drug Risperdal has slammed the company with an $8 billion verdict.

The award comes after more than three weeks of trial in the case Murray v. Janssen Pharmaceuticals. The award is the largest to date in the Risperdal litigation, which consists of nearly 7,000 cases pending in the Philadelphia Court of Common Pleas.